IL164921A0 - Synergistic interaction of abacavir and alovudine - Google Patents

Synergistic interaction of abacavir and alovudine

Info

Publication number
IL164921A0
IL164921A0 IL16492104A IL16492104A IL164921A0 IL 164921 A0 IL164921 A0 IL 164921A0 IL 16492104 A IL16492104 A IL 16492104A IL 16492104 A IL16492104 A IL 16492104A IL 164921 A0 IL164921 A0 IL 164921A0
Authority
IL
Israel
Prior art keywords
alovudine
abacavir
synergistic interaction
treatment
combined
Prior art date
Application number
IL16492104A
Other languages
English (en)
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0202022A external-priority patent/SE0202022D0/xx
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of IL164921A0 publication Critical patent/IL164921A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
IL16492104A 2002-06-27 2004-10-28 Synergistic interaction of abacavir and alovudine IL164921A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0202022A SE0202022D0 (sv) 2002-06-27 2002-06-27 Synergistic interaction of abacavir and alovudine
EP02024744 2002-11-06
PCT/SE2003/001100 WO2004002433A1 (en) 2002-06-27 2003-06-24 Synergistic interaction of abacavir and alovudine

Publications (1)

Publication Number Publication Date
IL164921A0 true IL164921A0 (en) 2005-12-18

Family

ID=30001852

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16492104A IL164921A0 (en) 2002-06-27 2004-10-28 Synergistic interaction of abacavir and alovudine

Country Status (19)

Country Link
US (1) US20060084627A1 (xx)
EP (1) EP1536800B1 (xx)
JP (1) JP2005533870A (xx)
KR (1) KR20050013628A (xx)
CN (1) CN1302779C (xx)
AT (1) ATE314851T1 (xx)
AU (1) AU2003239088B2 (xx)
BR (1) BR0311141A (xx)
CA (1) CA2481890A1 (xx)
DE (1) DE60303131T2 (xx)
ES (1) ES2254941T3 (xx)
HK (1) HK1079981B (xx)
IL (1) IL164921A0 (xx)
MX (1) MXPA04012754A (xx)
NO (1) NO20050445L (xx)
NZ (1) NZ535817A (xx)
PL (1) PL373758A1 (xx)
RU (1) RU2320347C2 (xx)
WO (1) WO2004002433A1 (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1610797A1 (en) * 2003-03-27 2006-01-04 Boehringer Ingelheim International GmbH Antiviral combination of nevirapine and a further antiretroviral compound
GB0608876D0 (en) 2006-05-05 2006-06-14 Medivir Ab Combination therapy
NZ627826A (en) * 2010-01-27 2016-01-29 Viiv Healthcare Co Antiviral combinations involving (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446029A (en) * 1986-07-04 1995-08-29 Medivir Ab Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides
SE8602981D0 (sv) * 1986-07-04 1986-07-04 Astra Laekemedel Ab Novel medicinal use
GB8719877D0 (en) * 1987-08-22 1987-09-30 Wellcome Found Antiviral compounds
NZ229453A (en) * 1988-06-10 1991-08-27 Univ Minnesota & Southern Rese A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
CA2340156C (en) * 1998-08-10 2007-10-23 Novirio Pharmaceuticals Limited .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
MXPA01007359A (es) * 1999-01-22 2003-09-22 Univ Emory Beta-d-2', 3'-dideshidro-2', 3`didesoxi-5-fluorocitidina para utilizarla en el tratamiento de infecciones por vih.
US6514979B1 (en) * 1999-03-03 2003-02-04 University Of Maryland Biotechnology Institute Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
WO2001093898A1 (en) * 2000-06-02 2001-12-13 Smithkline Beecham Corporation Methods of treating viral diseases with il-18 and il-18 combinations

Also Published As

Publication number Publication date
PL373758A1 (en) 2005-09-05
WO2004002433A1 (en) 2004-01-08
AU2003239088A1 (en) 2004-01-19
MXPA04012754A (es) 2005-03-23
NZ535817A (en) 2006-11-30
US20060084627A1 (en) 2006-04-20
ATE314851T1 (de) 2006-02-15
CN1302779C (zh) 2007-03-07
DE60303131T2 (de) 2006-07-20
AU2003239088B2 (en) 2006-11-02
ES2254941T3 (es) 2006-06-16
WO2004002433A8 (en) 2004-05-06
EP1536800B1 (en) 2006-01-04
NO20050445L (no) 2005-01-26
BR0311141A (pt) 2005-06-07
CA2481890A1 (en) 2004-01-08
EP1536800A1 (en) 2005-06-08
DE60303131D1 (de) 2006-03-30
HK1079981A1 (en) 2006-04-21
RU2320347C2 (ru) 2008-03-27
JP2005533870A (ja) 2005-11-10
CN1665509A (zh) 2005-09-07
RU2005101874A (ru) 2005-06-27
HK1079981B (zh) 2007-10-12
KR20050013628A (ko) 2005-02-04

Similar Documents

Publication Publication Date Title
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
IL136839A0 (en) Pharmaceutical compositions comprising cannabidiol derivatives
MY125978A (en) Admantane derivatives
MXPA03007712A (es) Sales farmaceuticas.
IL149147A0 (en) Use of oxcarbazepine for the manufacture of oral dosage form medicament
EP1259240B8 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
TW200600091A (en) Sulfonylethyl phosphorodiamidates
CA2428160A1 (en) Compositions for antitumor treatment containing ecteinascidin 743
HK1068606A1 (en) Novel aminobenzoephenones
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
HRP20041092A2 (en) New pharmaceutical compositions containing filbanserin polymorph a
IL150528A0 (en) Ibuprofen containing active agent preparation
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
HK1079981A1 (en) A pharmaceutical preparation comprising a abacavirand alovudine and use thereof
AU2003246566A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
HUP0204208A2 (hu) Pruritus kezelésére szolgáló külsőleges gyógyszerkészítmény
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
GB2443377A (en) Anti-malarial composition comprising artesunate and lumefantrine
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
AU2502301A (en) Medicament and combination of compatible medicaments
AU2002225097A1 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
MXPA03010920A (es) Uso de alconil l- carnitina para preparacion de medicamento para tratar anhedonia.
UA88468C2 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
IL162857A0 (en) Oral vaccination